Sun Pharmaceutical Industries Ltd. (Sun Pharma) has announced that the US Food and Drug Administration (FDA) has approved Ilumya (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Sun Pharma is headquartered in Mumbai, India, and Princeton, NJ.

Indications: Ilumya selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor leading to inhibition of the release of pro-inflammatory cytokines and chemokines.

Dosage/administration: Ilumya is administered at a dose of 100 mg by subcutaneous injection every 12 weeks, after the completion of initial doses at weeks 0 and 4. It is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients.

Adverse reactions: The most common (≥1%) adverse reactions associated with Ilumya treatment are upper respiratory infections, injection site reactions, and diarrhea.